NIDA

February 20, 2018

Based on UAMS Research, InterveXion Wins Grants, Partners with BioVentures’ Help

Ben Boulden

Misty Stevens demonstrates one of the lab procedures InterveXion uses in the development of the monoclonal antibody it is studying for possible future use in the treatment of methamphetamine addiction.

Feb. 20, 2018 | Truly good ideas like the one around which InterveXion was built have staying power. Since InterveXion was established as a company in 2004, granting agencies and others have continued to value both the company and its mission. BioVentures from the first saw merit in the new treatment for methamphetamine abuse developed…

June 24, 2015

UAMS Recruiting Adolescent Girls for Trauma Study

Kelly Gardner

LITTLE ROCK – A team of researchers at the University of Arkansas for Medical Sciences (UAMS) is recruiting girls ages 11-17 for a study of how child abuse can change brain function and increase the likelihood of adults developing mental health disorders. The study, at the UAMS Brain Imaging Research Center, is hoping to uncover…

January 26, 2015

UAMS Researchers Receive $538,781 Grant to Study Opioid Prescribing and Dispensing

Ben Boulden

Jan. 26, 2015 | Two University of Arkansas for Medical Sciences (UAMS) research scientists recently were awarded a three-year $538,781 grant by the National Institute on Drug Abuse (NIDA) to investigate the opioid prescribing and dispensing decision making processes of primary care providers and pharmacists.

UAMS Researchers Awarded $538,781 Grant to Study Opioid Prescribing and Dispensing

Ben Boulden

LITTLE ROCK – Two University of Arkansas for Medical Sciences (UAMS) research scientists recently were awarded a three-year $538,781 grant by the National Institute on Drug Abuse (NIDA) to investigate the opioid prescribing and dispensing decision making processes of primary care providers and pharmacists.